Last reviewed · How we verify

NCT06795321

Personality and Anesthesia Preferences in Cesarean Delivery

Completed Last updated 28 January 2025
What this trial tests

trial testing Spinal anesthesia in Cesarean Delivery in 150 participants. Completed in 1 November 2024.

Timeline
1 January 2024
Primary endpoint
1 September 2024
1 November 2024

Quick facts

Lead sponsorOndokuz Mayıs University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment150
Start date1 January 2024
Primary completion1 September 2024
Estimated completion1 November 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ondokuz Mayıs University

Who can join

Adults 18 to 45, female only, with Cesarean Delivery or Personality Beliefs. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cesarean deliveries (CD) under general anesthesia are still common despite higher risks. Clinical guidelines recommend neuraxial anesthesia, but many patients refuse it due to fear and anxiety. This study aims to compare the personality traits of mothers who chose general versus spinal anesthesia for CD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Patients' anesthesia preferences for Cesarean delivery: exploring the role of personality beliefs in spinal vs. General anesthesia.
    Turunc E, Bilgin S, Akdeniz S, Komurcu O, et al · · 2025 · PMID 40597644 · DOI 10.1186/s12871-025-03185-w

Verify or expand the search:

Other trials of Spinal anesthesia

Trials testing the same drug.

Other recruiting trials for Cesarean Delivery

Currently open trials in the same condition.

Other Ondokuz Mayıs University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06795321.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing